161 related articles for article (PubMed ID: 37662977)
1. A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication of
Li J; Lv L; Zhu Y; Zhou Z; He S
Infect Drug Resist; 2023; 16():5637-5645. PubMed ID: 37662977
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of vonoprazan combined with different dose amoxicillin on eradication of
Lin Y; Xu H; Yun J; Yu X; Shi Y; Zhang D
Ann Transl Med; 2022 Sep; 10(18):987. PubMed ID: 36267745
[TBL] [Abstract][Full Text] [Related]
3. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
Qian HS; Li WJ; Dang YN; Li LR; Xu XB; Yuan L; Zhang WF; Yang Z; Gao X; Zhang M; Li X; Zhang GX
Am J Gastroenterol; 2023 Apr; 118(4):627-634. PubMed ID: 36729890
[TBL] [Abstract][Full Text] [Related]
4. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chen S; Shen W; Liu Y; Dong Q; Shi Y
Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
[TBL] [Abstract][Full Text] [Related]
6. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
[TBL] [Abstract][Full Text] [Related]
8. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
Han S; Deng Z; Cheung K; Lyu T; Chan P; Li Y; Ni L; Luo X; Li K
BMC Gastroenterol; 2023 Jul; 23(1):231. PubMed ID: 37420205
[TBL] [Abstract][Full Text] [Related]
9. Clinical Study on the Eradication of Helicobacter pylori by Vonoprazan Combined with Amoxicillin for 10-Day Dual Therapy.
Yan K; Dai X; Li Z; Rong W; Chen L; Diao X
Clin Pharmacol Drug Dev; 2024 Mar; 13(3):240-247. PubMed ID: 38197874
[TBL] [Abstract][Full Text] [Related]
10. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating
Hu Y; Xu X; Liu XS; He C; Ouyang YB; Li NS; Xie C; Peng C; Zhu ZH; Xie Y; Shu X; Zhu Y; Graham DY; Lu NH
Front Immunol; 2022; 13():1049908. PubMed ID: 36726990
[TBL] [Abstract][Full Text] [Related]
11. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
Wang J; Li YY; Lin MJ; Liu J; Lin BS; Ding YM; Wan M; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
J Dig Dis; 2023 Jan; 24(1):19-27. PubMed ID: 36960538
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety comparison of
Wang Z; Wang F
Therap Adv Gastroenterol; 2022; 15():17562848221125308. PubMed ID: 36268270
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of
Zhang Z; Liu F; Ai F; Chen X; Liu R; Zhang C; Fang N; Fu T; Wang X; Tang A
Front Pharmacol; 2023; 14():1143969. PubMed ID: 37214450
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of vonoprazan-amoxicillin dual therapy for
Wang X; Teng G; Dong X; Dai Y; Wang W
Therap Adv Gastroenterol; 2023; 16():17562848231190976. PubMed ID: 37664169
[TBL] [Abstract][Full Text] [Related]
15. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Lu L; Wang Y; Ye J; Han Y; Lou G; Li Y; Yan H; Du Q
Helicobacter; 2023 Feb; 28(1):e12940. PubMed ID: 36458325
[TBL] [Abstract][Full Text] [Related]
16. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
Hu J; Mei H; Su NY; Sun WJ; Zhang DK; Fan LL; He P; Pan J; Wang XW; Zou PY; Liu YX; Guo Y; Lan CH
Helicobacter; 2023 Aug; 28(4):e12970. PubMed ID: 37160689
[TBL] [Abstract][Full Text] [Related]
17. Vonoprazan on the Eradication of Helicobacter pylori Infection.
Huang J; Lin Y
Turk J Gastroenterol; 2023 Mar; 34(3):221-226. PubMed ID: 36511603
[TBL] [Abstract][Full Text] [Related]
18. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
[TBL] [Abstract][Full Text] [Related]
19. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
